Search by conditions:


Protocol Description Phase
15-590 A single arm phase 2 study of the dual mTORC1/mTORC2 inhibitor AZD2014 provided on an intermittent schedule for neurofibromatosis 2 patients with progressive or symptomatic meningiomas  (View details on Phase II
12-466 Open-label, Phase 2 Study of Bevacizumab in Children with Neurofibromatosis 2 and Progressive Vestibular Schwannomas that are Poor Candidates for Standard Treatment with Surgery or Radiation  (View details on Phase II
2 clinical trials listed

Back to Top